Biomedicine and Pharmacy
The biomedical cluster is experiencing a technological boom. According to Scopus, the investment vector is shifting towards the Global South, where state funds from China surpass the US in medical research funding volumes. The global frontier is dominated by artificial intelligence technologies in diagnostics, the study of ferroptosis in oncology, and mRNA technologies.
(AI in Diagnostics)
(Ferroptosis and Oncology)
(Lens.org)
Grant Flows
(TOP GLOBAL FUNDS)
An analysis of global funding based on SciVal data demonstrates fierce competition. The largest sponsor of global medical research is the National Natural Science Foundation of China (NSFC). The Sankey diagram below presents the volume of supported research: the flows reflect the number of published scientific articles funded by the respective organization.
Global Frontier: Hot Topics
(TOP 1% BY PROMINENCE)
The bubble chart, based on SciVal metrics, visualizes the most relevant areas in biomedicine (Top 1% Prominence). The size of the elements is proportional to the total number of publications in Scopus, and the position on the Y-axis reflects the citation impact of the papers (FWCI). The industry is led by machine learning algorithms, genome editing technologies, and immunotherapy.
Geography of Patenting
(TOP 5 JURISDICTIONS)
Unlike publications, in the intellectual property market, according to Lens.org, the USA confidently maintains absolute leadership (857 thousand documents), ahead of China.
* Europe (EPO) — European Patent Office (regional patents).
Leading Developers
(TOP 5 CORPORATIONS)
The global patent market, according to Lens.org data, is monopolized by transnational "Big Pharma". The leaders include L'Oreal, Novartis, and Hoffmann-La Roche.
Global Competitiveness Assessment
The university's medical cluster demonstrates stable results at the national level, but faces challenges in the international arena. The decomposition of metrics records growth in technology transfer (Industry) indicators and the expansion of the international network (International Research Network), despite a correction in Academic Reputation. Independent scientometric benchmarking (SciVal) defines the vector for strategic development: focus on high-ranking journals (Top 10%) and increasing the field-weighted citation impact (FWCI).
RAEX
Medicine 2026
THE WUR
Clinical and Health 2026
QS
Medicine 2026
QS
Pharmacy & Pharmacology 2025
Benchmarking: Journals
(SHARE OF ARTICLES IN TOP 10% GLOBAL JOURNALS)
According to SciVal, the share of articles in top-tier journals (3.3%) exceeds the indicator of Pirogov Russian National Research Medical University (2.8%), reflecting a focus on quality.
Benchmarking: Impact (FWCI)
(ZONE OF STRATEGIC GROWTH)
According to SciVal, the current FWCI level indicates the need to strengthen international collaborations to overcome the gap with the leaders.
Human Resources Potential and Clinical Specialization
The development of biomedical science at the university is based on strong research teams specializing in surgery, obstetrics, and oncology. The priority is the Open Access publication model and targeted, highly impactful technology transfer to the industry.
Cluster Leaders
Zhanna Kobalava
CardiologyLeading researcher in the field of cardiology. Demonstrates a high level of collaboration with the corporate sector (almost 10% of publications).
Albert Sufianov
NeurosurgerySpecialist in the field of clinical neurology and neurosurgery. Shows a phenomenal level of international collaboration (71.2% of publications).
Mekan Orazov
Obstetrics and GynecologySpecialist in the field of gynecology, endocrinology, and reproductive medicine. Regularly publishes research integrating various aspects of women's health.
Openness Transformation
(OPEN ACCESS vs CLOSED)
According to Scopus, over five years, the volume of Open Access (Gold OA) articles increased from 316 to 511, consistently exceeding the share of closed publications.
Clinical Specialization
(CLUSTER STRUCTURE IN SCOPUS)
An analysis of sub-areas in SciVal shows the dominance of applied clinical disciplines: surgery, oncology, obstetrics, and infectious diseases.
Collaboration with Industry (Technology Transfer)
According to SciVal, the share of joint publications with the corporate sector (pharmaceutical companies) is 1.2% (49 articles). However, their citation rate (FWCI 6.91) is almost 7 times higher than the global average, which confirms the highest quality and demand for applied medical research.
India
Cooperation with Indian research centers is a crucial element in the development of the university's biomedical field. India, as a global hub for pharmacology and biotechnology, provides unique opportunities for joint research. Analytics confirm the highest quality (FWCI) of joint publications with Indian academic and clinical centers.
Partnership Dynamics
(TOTAL VOLUME AND FWCI OF JOINT PUBLICATIONS IN MEDICINE)
The chart (based on SciVal data) presents the dynamics of joint publications. The average field-weighted citation impact (FWCI) reaches 9.10, which indicates a colossal demand for the works.
Key Centers (India)
SciVal analytics show that Indian medical institutes form a solid foundation for international projects. The dominance of clinical centers (AIIMS) and specialized universities in the structure of collaborations indicates a concentration of efforts in the field of practical healthcare and pharmacy.
| Organization | Joint Articles |
|---|---|
| Saveetha Institute of Medical and Technical Sciences | 10 |
| All India Institute of Medical Sciences (AIIMS Jodhpur) | 9 |
| Public Health Foundation of India | 8 |
| Manipal Academy of Higher Education | 8 |
| All India Institute of Medical Sciences (AIIMS New Delhi) | 7 |
Most Cited Publications (Top 3)
Consortium mega-collaborations (>50 authors) are excluded from the sample to reflect the actual contribution of specific research teams.
Published in Chemosphere.
Published in Biomedicines.
Published in Biomedical Signal Processing and Control.